ImmuCell Ownership
| ICCC Stock | USD 5.50 0.27 5.16% |
Shares in Circulation | First Issued 2009-03-31 | Previous Quarter 8 M | Current Value 8 M | Avarage Shares Outstanding 5 M | Quarterly Volatility 2.1 M |
ImmuCell |
ImmuCell Stock Ownership Analysis
About 40.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.76. Some equities with similar Price to Book (P/B) outperform the market in the long run. ImmuCell has Price/Earnings (P/E) ratio of 195.0. The entity recorded a loss per share of 0.49. The firm had not issued any dividends in recent years. ImmuCell had 1:100 split on the 25th of July 1990. ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people. To learn more about ImmuCell call Michael Brigham at 207 878 2770 or check out https://immucell.com.Besides selling stocks to institutional investors, ImmuCell also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different ImmuCell's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align ImmuCell's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
ImmuCell Quarterly Liabilities And Stockholders Equity |
|
ImmuCell Insider Trades History
About 40.0% of ImmuCell are currently held by insiders. Unlike ImmuCell's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against ImmuCell's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of ImmuCell's insider trades
ImmuCell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ImmuCell is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ImmuCell backward and forwards among themselves. ImmuCell's institutional investor refers to the entity that pools money to purchase ImmuCell's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Prosperity Planning, Inc. | 2024-09-30 | 16 K | Ubs Group Ag | 2024-09-30 | 15.9 K | Blackrock Inc | 2024-09-30 | 14.3 K | Mesirow Fin Investmt Mgmt Intl Equity | 2024-09-30 | 12.2 K | Essex Financial Services, Inc. | 2024-09-30 | 11 K | Hm Payson & Co | 2024-09-30 | 4 K | Bank Of America Corp | 2024-09-30 | 2.1 K | Tower Research Capital Llc | 2024-09-30 | 1.1 K | Jones Financial Companies Lllp | 2024-09-30 | 19.0 | Cresset Asset Management, Llc | 2024-09-30 | 264 K | Vanguard Group Inc | 2024-09-30 | 225.6 K |
ImmuCell Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmuCell insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmuCell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ImmuCell insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ImmuCell Outstanding Bonds
ImmuCell issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ImmuCell uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ImmuCell bonds can be classified according to their maturity, which is the date when ImmuCell has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US45258LAA52 Corp BondUS45258LAA52 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
ImmuCell Corporate Filings
8K | 16th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 17th of September 2024 Other Reports | ViewVerify | |
F3 | 27th of August 2024 The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in ImmuCell. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade ImmuCell Stock refer to our How to Trade ImmuCell Stock guide.You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ImmuCell. If investors know ImmuCell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ImmuCell listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.63) | Earnings Share (0.49) | Revenue Per Share | Quarterly Revenue Growth 0.549 | Return On Assets |
The market value of ImmuCell is measured differently than its book value, which is the value of ImmuCell that is recorded on the company's balance sheet. Investors also form their own opinion of ImmuCell's value that differs from its market value or its book value, called intrinsic value, which is ImmuCell's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ImmuCell's market value can be influenced by many factors that don't directly affect ImmuCell's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ImmuCell's value and its price as these two are different measures arrived at by different means. Investors typically determine if ImmuCell is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ImmuCell's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.